Molecular Magnetic Resonance Imaging of Tumors with a PTPµ Targeted Contrast Agent  by Burden-Gulley, Susan M et al.
Molecular Magnetic Resonance
Imaging of Tumors with a
PTPμ Targeted Contrast Agent1
Susan M. Burden-Gulley*,2, Zhuxian Zhou†,2,
Sonya E.L. Craig*, Zheng-Rong Lu†
and Susann M. Brady-Kalnay*,‡
*Department of Molecular Biology and Microbiology,
School of Medicine, Case Western Reserve University,
Cleveland, OH; †Department of Biomedical Engineering,
School of Engineering, Case Western Reserve University,
Cleveland, OH; ‡Department of Neurosciences, School of
Medicine, Case Western Reserve University, Cleveland, OH
Abstract
Molecular magnetic resonance imaging (MRI) of tumors improves the specificity of MRI by using targeted probes
conjugated to contrast-generating metals. The limitation of this approach is in the identification of a target molecule
present in sufficient concentration for visualization and the development of a labeling reagent that can penetrate
tumor tissue with the fast kinetics required for use in a clinical setting. The receptor protein tyrosine phosphatase
PTPμ is a transmembrane protein that is continuously proteolyzed in the tumor microenvironment to generate a high
concentration of extracellular fragment that can be recognized by the SBK2 probe.We conjugated the SBK2 peptide to
a gadolinium chelate [SBK2-Tris-(Gd-DOTA)3] to test whether the SBK2 probe could be developed as anMRmolecular
imaging probe. When intravenously injected into mice bearing flank tumors of human glioma cells, SBK2-Tris-
(Gd-DOTA)3 labeled the tumors within 5 minutes with a high level of contrast for up to 2 hours post-injection. The
contrast enhancement of SBK2-Tris-(Gd-DOTA)3 was significantly higher than that observed with a current MRI
macrocyclic gadolinium chelate (Gadoteridol, ProHance) alone or a scrambled control. These results demonstrate
that SBK2-Tris-(Gd-DOTA)3 labeling of the PTPμ extracellular fragment is a more specific MRmolecular imaging probe
than ProHance or a scrambled control. Consequently, the SBK2 probe may be more useful than the current gold
standard reagent for MRI to identify tumors and to co-register tumor borders during surgical resection.
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Introduction
Magnetic resonance imaging (MRI) offers excellent spatial resolution
while providing basic anatomic detail when used to image tumors.
MRI is currently the preferred method of tumor imaging before sur-
gery. Yet MRI is limited to delineating only the gross anatomy of
tumors. In the case of brain tumors, MRI has a limited ability to high-
light the complex and irregular shapes of tumors and lacks biologic
specificity, as the technology images areas of increased blood-brain
barrier permeability but not necessarily the full extent of the tumor
itself [1]. To improve on the specificity of MRI, molecular MRI has
been introduced to label proteins in the area of interest using probes
that are conjugated to contrast-generating metals, such as iron oxide
or gadolinium chelates [2]. These modifications have their limitations
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as detection levels of metal ions are in the micromolar range, whereas
target proteins tend to be expressed in the nanomolar range, resulting
in a disconnect between the quantity of label and labeling agent able
to penetrate into a tumor [2]. Amplification methods have been
employed to overcome this limitation, including exogenous enzymatic
amplification paradigms [3].
An alternative target is one that is biologically amplified by con-
tinuous endogenous enzymatic processing and deposition and is there-
fore found in high concentration in the tumor microenvironment.
The receptor protein tyrosine phosphatase PTPμ is an example of a
transmembrane protein that is proteolyzed in the tumor microenvi-
ronment, but not in normal tissue, to yield an extracellular fragment
and a membrane-free intracellular fragment [4,5]. The proteolyzed
extracellular fragment of PTPμ is retained in the tumor vicinity and
is enriched in the tumor microenvironment of the dispersing tumor cell
population typical of glioblastoma multiforme (GBM) [6]. GBM is a
devastating cancer of the brain because of the aggressively dispersive/
invasive GBM cells [7]. A fluorescent probe that binds to the PTPμ
extracellular fragment labels both the main GBM tumor mass in the
brain [4] and greater than 99% of the dispersing cells up to 3.5 mm
away from the main tumor [6]. The fluorescent probe, named SBK2, is
a highly sensitive marker that could possibly be used during neuro-
surgical resection. Fluorescence imaging cannot, however, be used for
brain tumor imaging in patients before surgery because of the limited
depth of penetration of the fluorescent light signal.
To test whether the SBK2 probe could be developed as a diagnostic
imaging tool, we conjugated it to a gadolinium chelate [SBK2-Tris-
(Gd-DOTA)3] to generate an MR-detectable SBK2 probe. We com-
pared the ability of SBK2-Tris-(Gd-DOTA)3 to function as a contrast
agent compared to a current MRI macrocyclic gadolinium chelate
(Gadoteridol, ProHance) alone or to a scrambled probe linked to
gadolinium [scrambled Tris-(Gd-DOTA)3]. When intravenously in-
jected into mice bearing flank tumors of human glioma cells, SBK2-
Tris-(Gd-DOTA)3 labeled the tumors within 5 minutes with a high
level of contrast persisting for 2 hours post-injection. The contrast
enhancement of SBK2-Tris-(Gd-DOTA)3 was significantly higher
than that observed with ProHance alone. These results demonstrate
that SBK2-Tris-(Gd-DOTA)3 labeling of PTPμ extracellular fragment
retained in the tumor microenvironment is a more specific MR molec-
ular imaging probe than a nonspecific gadolinium chelate and may be a
useful tool for diagnosis of the extent of tumor dispersal before surgery
and co-registering GBM tumor borders during surgical resection.
Materials and Methods
All reagents were used without further purification unless otherwise
stated. Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluoro-
phosphate, 1-hydroxybenzotriazole hydrate, 2-chlorotritylchloride
resin, and all of the Fmoc-protected amino acids were purchased
from Chem-Impex International, Inc (Wood Dale, IL). Anhydrous
N ,N -diisopropylethyl amine and N ,N -dimethylformamide were pur-
chased from Alfa Aesar (Ward Hill, MA). Trifluoroacetic acid was pur-
chased from Oakwood Products, Inc (West Columbia, SC). The
detailed synthesis of maleimido-Tris-propargyl and azido-(Gd-DOTA)
is the subject of a forthcoming publication.
Synthesis and Characterization of SBK2-Tris-(Gd-DOTA)3
and Scrambled Tris-(Gd-DOTA)3
The SBK2 peptide was conjugated to Gd-DOTA using an increased
molar ratio of Gd-DOTA monoamide to peptide to generate an
MR-visible probe [SBK2-Tris-(Gd-DOTA)3]. A scrambled version of
the SBK2 peptide was used to generate a nontargeted control agent
[scrambled Tris-(Gd-DOTA)3]. Peptide SBK2 with an N-terminal
cysteine (C-GEGDDFNWEQVNTLTKPTSD) was synthesized using
standard solid-phase peptide synthesis. Matrix-assisted laser desorption/
ionization time-of-flight (MALDI-TOF; Autoflex Speed, Bruker) mass
spectra (m/z,M+) were given as follows: 2355.52 (observed) and 2355.00
(calculated). Scrambled peptide (C-GFTQPETGTDNDLWSVDNEK)
was synthesized by the same method [MALDI-TOF (m/z, M+):
2355.56 (observed); 2355.00 (calculated)]. SBK2 was conjugated to
maleimido-Tris-propargyl, then subsequently to azido-(Gd-DOTA).
The reaction was traced by MALDI-TOF until Gd-DOTA was fully
attached [MALDI-TOF (m/z, M+): 4664.87 (observed); 4664.62
(calculated); Inductively coupled plasma optical emission spectroscopy
(ICP-OES) analysis for Gd3+ content: 9.56% (observed); 10.1%
(calculated)]. Scrambled Tris-(Gd-DOTA)3 was synthesized by the
same method with a yield of 68% [MALDI-TOF (m/z, M+):
4664.75 (observed); 4664.62 (calculated); ICP (Gd3+ content): 9.68%
(observed); 10.1% (calculated)].
The gadolinium content was measured by ICP-OES (Agilent 730
Axial ICP-OES; Agilent Technologies, Wilmington, DE). Relaxation
times were measured at 60 MHz (1.5 T) using a Bruker Minispec
Relaxometer at 37°C. T1 was measured with an inversion recovery pulse
sequence. T 2 was measured using a Carr-Purcell-Meiboom-Gill
sequence with 500 echoes collected.
Cell Culture and Flank Tumor Implants
The human LN-229 glioma cell line was purchased from American
Type Culture Collection (Manassas, VA) and cultured in Dulbecco’s
modified Eagle’s medium supplemented with 5% FBS. Cells were
infected with lentivirus encoding green fluorescent protein (GFP),
diluted in BD Matrigel Matrix (BD Biosciences, Franklin Lakes,
NJ), and injected into both flanks of female nude athymic mice
(NCr-nu/+, NCr-nu/nu, 20–25 g each) as previously described [4].
Approximately 1.4 × 106 cells were implanted per flank. To correlate
tumor position with GFP fluorescence, mice were imaged using the
Maestro FLEX In Vivo Imaging System as previously described [4].
Tumor area was approximately 0.5 cm2, as measured from GFP fluo-
rescence images acquired with the Maestro just before MRI.
Molecular Imaging of Tumors with MRI
The MRI study was performed using a Bruker Biospec 7-T MRI
scanner (Bruker Corp, Billerica, MA) with a 72-mm diameter cylin-
drical radio frequency coil. Mice bearing LN-229 flank tumors were
imaged at 2 to 5 weeks after tumor implant. Mice were anesthetized
with a 2% isoflurane-oxygen mixture in an isoflurane induction cham-
ber. Tail veins were catheterized with a 30-gauge needle connected to
a 1.2-m-long small diameter Tygon tubing filled with heparinized
saline. The animals were moved into a magnet and kept under inhala-
tion anesthesia with 1.5% isoflurane-oxygen through a nose cone. A
respiratory sensor connected to a monitoring system (SA Instruments,
Stony Brook, NY) was placed on the abdomen to monitor rate and
depth of respiration. The body temperature was maintained at 37°C
by blowing hot air into the magnet through a feedback control system.
A group of three mice was used for each agent per experiment. Sagittal
section images were acquired with a localizing sequence to identify the
tumor location, followed by a fat suppression three-dimensional (3D)
FLASH sequence [repetition time (TR) = 8.5ms, echo time (TE) = 2.6ms,
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average = 3, 30° flip angle, in-plane field of view (FOV) = 10 cm, 25-mm
slab thickness] and a two-dimensional (2D) T 1-weighted spin echo
sequence (TR = 500 ms, TE = 8.1 ms, average = 2, in-plane FOV = 3 cm,
1.2-mm slice thickness) before injection. After pre-injection baseline
MRI acquisition, ProHance, the targeted SBK2 agent, or the nontargeted
scrambled control was injected at a dose of 0.03 or 0.1 mmol Gd/kg
by flushing with 60 μl of heparinized saline. Images were then acquired
using the same sequences at 13 different time points after the injection
for up to 120 minutes.
Image Processing and Analysis
Image analysis was performed by using Bruker ParaVision 4.0 im-
aging software. Regions of interest were drawn over the whole tumor
in the 2D imaging plane and average signal intensity was measured.
Contrast-to-noise ratios (CNRs) in the tumor were calculated at each
time point and averaged from different mice (n = 3) using the fol-
lowing equation: CNR = (S t − Sm)/(δn), where S t and Sm denote the
signal in tumor and adjacent thigh muscle and δn is the SD of noise
estimated from the background air. The P values were calculated
using a two-tailed Student’s t test, assuming statistical significance
at P < .05. Color-coded display of relative contrast intensity in tumor
was processed by SPIN (signal processing in NMR) software (MRI
Institute for Biomedical Research, Detroit, MI).
Biodistribution Study
Mice from the MRI study were sacrificed at 7 days post-injection.
The organ and tissue samples, including the brain, heart, kidneys, liver,
lungs, spleen, skin, muscle, femur, and tumor, were resected and
weighed. The tissue samples were liquified with nitric acid and prepared
for ICP-OES measurement as previously described [8]. The average
gadolinium content in each sample was measured by ICP-OES (n =
3 per contrast agent). The Gd content was calculated as the percentage
of injected dose per gram of organ/tissue (% ID/g).
Figure 1. Structure and characterization of PTPμ targeted and control contrast agents. (A) The structure of the targeted contrast agent
SBK2-Tris-(Gd-DOTA)3 is shown. (B) MALDI-TOF mass spectra characterization of the nontargeted control [scrambled Tris-(Gd-DOTA)3]
and targeted contrast agent [SBK2-Tris-(Gd-DOTA)3]. (C) Plots of relaxivity versus the concentration of gadolinium (mM) of the contrast
agents scrambled Tris-(Gd-DOTA)3 and SBK2-Tris-(Gd-DOTA)3.
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Histologic Analysis of Tumor Tissue Sections
LN-229–GFP flank tumors were excised and fixed with 4% para-
formaldehyde in PEM buffer (80 mM Pipes, 5 mM EGTA, 1 mM
magnesium chloride, 3% sucrose), pH 7.4, at 72 hours post-MR
molecular imaging to allow for clearance of contrast agents. Tumors
were embedded in Tissue Freezing Medium (Electron Microscopy
Sciences, Hatfield, PA) in a dry ice ethanol slurry and cryosectioned
at 7-μm intervals.
For probe labeling, tissue sections were blocked with 2% goat serum
in phosphate-buffered saline for 20 minutes at room temperature, then
incubated with SBK2–Texas Red or scrambled Texas Red probes [4,5]
diluted to 1 μM in block buffer for 1 hour at room temperature in dark
conditions. The sections were rinsed with phosphate-buffered saline,
coverslipped with Citifluor Antifadent Mounting Medium (Electron
Microscopy Sciences), and imaged immediately at ×20 magnification
on a Leica DMI 6000 B inverted microscope (Leica Microsystems
GmbH, Wetzlar, Germany) using a Retiga EXi camera (QImaging,
Surrey, BC) andMetamorph software (MolecularDevices,Downington,
PA). Images were acquired across the entire tissue using bright-field
and fluorescence optics for fluorescein (GFP) and Texas Red (probe).
The resultant images were tiled and flattened to form a single com-
posite image using Metamorph software. A human specific Vimentin
antibody (clone SP20; Thermo Fisher Scientific, Fremont, CA)
was used to detect the implanted LN-229 tumor cells and imaged
as above.
Results
Synthesis and Characterization of SBK2-Tris-(Gd-DOTA)3
and Scrambled Tris-(Gd-DOTA)3
The SBK2 peptide was conjugated to Gd-DOTA using an increased
molar ratio of Gd-DOTA monoamide to peptide to generate an
MR-visible probe [SBK2-Tris-(Gd-DOTA)3] for effective targeted
contrast enhancement (Figure 1A). The final product had good water
solubility. A scrambled version of the SBK2 peptide was used to gen-
erate a nontargeted control agent [scrambled Tris-(Gd-DOTA)3]. The
final products were characterized by MALDI-TOF (Figure 1B) and
ICP-OES and with a Bruker Minispec Relaxometer. Both targeted
and control contrast agents had similar relaxivity (Figure 1C).
Figure 2. The SBK2 targeted contrast agent greatly improves the enhancement of LN-229 tumors. (A) Representative T 1-weighted axial
2D gradient images of LN-229 flank tumor–bearing mice before (pre-injection) and at 1, 5, 10, 20, and 30 minutes after the intravenous
injection of ProHance, scrambled Tris-(Gd-DOTA)3, or SBK2-Tris-(Gd-DOTA)3 at 0.1 mmol Gd/kg [n= 7 tumors from four mice for ProHance;
n= 11 tumors from six mice for both SBK2-Tris-(Gd-DOTA)3 and SBK2-Tris-(Gd-DOTA)3]. White arrow indicates tumor. (B) Axial 2D gradient
images shown in A with heat map overlays on the tumor to indicate contrast intensity. Color-coded key indicates relative level of contrast
intensity with red being the most intense.
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MR Tumor Molecular Imaging with SBK2-Tris-(Gd-DOTA)3
Athymic (nu/nu) mice bearing LN-229 flank tumors (2–5 weeks
post-implantation) were used for MRI studies. 2D axial T 1-weighted
gradient echo images of mice were acquired before injection of contrast
agents, then at 1-, 5-, 10-, 15-, 20-, 25-, and 30-minute intervals
following intravenous injection of either ProHance, scrambled Tris-
(Gd-DOTA)3, or SBK2-Tris-(Gd-DOTA)3 administered at a dose of
0.1 mmol/kg (Figure 2). Representative examples of 2D axial images
are shown in Figure 2A for each contrast agent, with tumors indicated
by white arrows. In comparison with the nontargeted contrast agents,
the targeted SBK2-Tris-(Gd-DOTA)3 agent resulted in greater
enhancement of tumors that was maintained for a longer period of time
(Figure 2A). This improved tumor enhancement is better illustrated
with heat map intensity overlays applied to the tumor regions (Fig-
ure 2B). The color key indicates the relative enhancement level from
lowest (purple) to highest (red). The tumor enhancement generated
by the SBK2-Tris-(Gd-DOTA)3 was greater than that observed for
the scrambled or ProHance agents (Figure 2B). Digitally magnified
MRI and heat map intensity images show greater detail of the tumor
enhancement achieved with each contrast agent for three separate
tumors per agent (Figure 3). The entire tumor was enhanced over
adjacent tissues with all of the contrast agents evaluated. ProHance
and scrambled Tris-(Gd-DOTA)3 resulted in enhanced contrast of
the tumor edge compared with the tumor center. This heterogeneous
pattern is not due to necrosis because the LN-229 tumors grow slowly
and do not exhibit necrosis in the time frame examined here. In com-
parison, the SBK2-Tris-(Gd-DOTA)3 resulted in the most intense
tumor enhancement, particularly in the tumor center. These results sug-
gest that active targeting of the tumor with SBK2-Tris-(Gd-DOTA)3
achieved greater penetration and contrast of the entire tumor.
To examine the biodistribution of each contrast agent, 3D longitu-
dinal T 1-weighted gradient echo images were also acquired for each
mouse (Figure 4). Contrast enhancement was observed in kidneys
and other major organs at the earliest time points but was significantly
decreased at later time points. Alternatively, enhancement of the uri-
nary bladder (white arrows in Figure 4) increased over time with all
labeling agents, suggesting that the unbound agents were being cleared
through renal filtration.
Quantitative Tumor Signal Analysis
Comparison of tumor enhancement was done using quantitative
signal analysis. Regions of interest were drawn over the tumor and
adjacent muscle tissue for each mouse, and the CNR was determined
at each time point following injection of contrast agents. Dose-response
tumor signal analysis was performed for ProHance or SBK2-Tris-(Gd-
DOTA)3 administered at 0.03 mmol/kg or 0.1 mmol/kg (Figure 5A).
The results indicate that the tumor contrast achieved with SBK2-
Tris-(Gd-DOTA)3 at 0.1 mmol/kg was significantly greater over
the entire 30-minute period than that achieved with ProHance at
0.1 mmol/kg (P < .05). Similar results were observed when compar-
ing SBK2-Tris-(Gd-DOTA)3 administered at 0.03 mmol/kg with
ProHance (0.03 mmol/kg) at 10 to 30 minutes post-injection (P <
.05). Of interest, the lowest dose of SBK2-Tris-(Gd-DOTA)3 (0.03
mmol/kg) resulted in tumor contrast that was similar to the contrast
achieved with the highest dose of ProHance (0.1 mmol/kg). These
results suggest that the targeted SBK2-Tris-(Gd-DOTA)3 is superior
for tumor enhancement.
To evaluate the dynamics of tumor enhancement over a longer period
of time, quantitative signal analysis was performed in tumors over
a 2-hour period following injection of contrast agents (Figure 5B).
The targeted agent SBK2-Tris-(Gd-DOTA)3 showed improved tumor
CNRwhen compared with the nontargeted scrambled Tris-(Gd-DOTA)3
Figure 3. Digitally magnified axial 2D gradient images of tumors
with heat map intensity overlays. Zoomed views of 5-minute T 1-
weighted axial 2D gradient images of LN-229 flank tumor–bearing
mice illustrate details of the heatmap intensity overlay in the tumors.
Three representative examples are shown for the ProHance control,
scrambled Tris-(Gd-DOTA)3 (scrambled), and SBK2-Tris-(Gd-DOTA)3
(SBK2) probes. Color-coded key indicates relative level of contrast
intensity with red being the most intense.
Figure 4. Distribution and clearance of control or PTPμ targeted con-
trast agents following intravenous administration in xenograft mice.
Representative T 1-weighted longitudinal 3D maximum intensity
projection images of mice bearing LN-229 flank tumors before
(Pre) and at 1, 5, 10, 15, 20, 25, and 30 minutes after intravenous
injection of ProHance, scrambled Tris-(Gd-DOTA)3, or SBK2-Tris-
(Gd-DOTA)3 contrast agents at 0.1 mmol Gd/kg in nude mice [n = 4
for ProHance; n = 6 for both scrambled Tris-(Gd-DOTA)3 and SBK2-
Tris-(Gd-DOTA)3]. Arrow indicates bladder localization.
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or ProHance. SBK2-Tris-(Gd-DOTA)3 resulted in an approximate
55% increase in tumor CNR over scrambled Tris-(Gd-DOTA)3 or
ProHance at 15 to 45 minutes post-injection (P < .001). At 60 to
120 minutes post-injection, the ProHance cleared more rapidly than
SBK2-Tris-(Gd-DOTA)3 resulting in greater than 110% increase in
SBK2-Tris-(Gd-DOTA)3 tumor CNR compared with ProHance (P <
.001). The SBK2-Tris-(Gd-DOTA)3 tumor CNR was approximately
53% greater than the scrambled Tris-(Gd-DOTA)3 tumor CNR at
60 to 90 minutes (P < .001). The larger size of the scrambled Tris-
(Gd-DOTA)3 probe in comparison with ProHance may be partially
responsible for its slower clearance rate between 60 and 120 minutes.
Biodistribution in Tissues
Tissue clearance of the targeted probes is important to avoid the
accumulation of toxic gadolinium ions. The biodistribution of gado-
linium was examined in the brain, heart, kidneys, liver, lungs, spleen,
skin, muscle, femur, and tumor at 7 days post-injection of the ProHance,
scrambled Tris-(Gd-DOTA)3, or SBK2-Tris-(Gd-DOTA)3 (Figure 6).
The gadolinium retention of scrambled Tris-(Gd-DOTA)3 and SBK2-
Tris-(Gd-DOTA)3 was similar in all tissues. Low residual accumulation
of approximately 0.39%, 0.91%, and 0.14% of injected targeted SBK2-
Tris-(Gd-DOTA)3 per gram of tissue was detected in spleen, kidney,
and liver, while less than 0.1% was detected in all other tissues, includ-
ing tumor. Accumulation of gadolinium from ProHance was less than
0.1% for all tissues examined.
Histology/Tumor Binding Specificity
LN-229–GFP flank tumors used for MRI were excised, fixed, and
cryosectioned for histologic analysis. Zoomed MR and corresponding
heat map images for the tumor are shown (Figure 7A). The hetero-
geneous signal enhancement in the heat map overlay suggests that the
target of the SBK2-Tris-(Gd-DOTA)3 probe was concentrated in the
tumor center and at the outer edge of the tumor. The corresponding
flank tumor sections were incubated with SBK2–Texas Red or scram-
bled Texas Red probes [4,5]. SBK2–Texas Red labeled the entire tumor
with greatest intensity in the tumor center (Figure 7B). This pattern is
similar to that observed in the MR images following labeling with the
SBK2-Tris-(Gd-DOTA)3 probe. In contrast, the scrambled Texas Red
Figure 5. Quantitation of LN-229 flank tumor enhancement following intravenous administration of control or targeted contrast agents in
xenograft mice. (A) Dose-response plots of LN-229 flank tumor CNR with ProHance or SBK2-Tris-(Gd-DOTA)3 administered at 0.03 mmol
Gd/kg (n= 3 per condition) or 0.1 mmol Gd/kg [n= 7 tumors from four mice for ProHance; n= 11 tumors from six mice for SBK2-Tris-(Gd-
DOTA)3]. (B) Comparison of LN-229 flank tumor CNR over a 2-hour period following intravenous administration of ProHance, scrambled
Tris-(Gd-DOTA)3, or SBK2-Tris-(Gd-DOTA)3 contrast agents (0.1 mmol Gd/kg; n = 6 tumors from three mice per condition). Data shown
as means ± SEM.
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probe did not label the tumor (Figure 7B). These data indicate that
the SBK2 probe recognized the flank tumors both in vitro and in vivo.
Anti-human vimentin antibody was used to label all the human cells
in the mouse flank. There is co-registration of the GFP-positive and
vimentin-positive cells (Figure 7, A and B), demonstrating that all
GFP-positive cells in the tumor xenograft are of human origin. The
LN-229 flank tumor is encapsulated by GFP-negative cells and matrix,
as shown in the magnified bright-field images in Figure 7C . The
proteolyzed extracellular fragment of PTPμ is retained both in the main
tumor and, to a lower extent, in the encapsulated region, as illustrated by
labeling with the SBK2–Texas Red probe (Figure 7C). Similar gradients
of PTPμ extracellular fragment, as detected by the SBK2 probe, have
been observed previously [4].
Discussion
In this publication, we demonstrate that the SBK2 probe can achieve
better tumor contrast enhancement than the nonspecific clinical con-
trast agent currently in use. The SBK2 probe targets PTPμ molecules
enriched in the tumor microenvironment and, in so doing, improves
the specificity of tumor enhancement. We previously conjugated the
SBK2 peptide to a fluorescent molecule and were able to detect it in
GBM cells in vivo using preclinical imaging modalities [4,6]. We now
demonstrate that the SBK2 probe can be used for clinical imaging
(MRI) in addition to its aforementioned use in preclinical and histo-
logic staining of GBM tumors.
PTPμ is a cell-cell adhesionmolecule that mediates adhesion through
a homophilic binding mechanism. Adhesive domains within the extra-
cellular segment of PTPμ are critical for mediating homophilic binding
[9]. The key adhesive domains are retained in the PTPμ extracellular
fragment that accumulates in association with glial brain tumors,
specifically GBM, but not in normal brain [4]. The presence of this
extracellular adhesive fragment prompted the development of the
SBK2 probe to bind homophilically to the fragments to label GBM
tumor cells and their microenvironment [4,6]. In this study, we dem-
onstrate that SBK2-Tris-(Gd-DOTA)3 intensely labeled both the
tumor core and the edge within 5 minutes (Figures 2 and 3). The
signal remained strong for 90 minutes post-injection and provided
greater contrast than ProHance for 2 hours after injection (Figure 5).
We conclude that the kinetics of SBK2-Tris-(Gd-DOTA)3 labeling
of GBM cells in vivo will allow ample time to perform MRI in a
clinical setting.
To compare ProHance to the molecular imaging agent SBK2-Tris-
(Gd-DOTA)3 and its scrambled control, all agents were dosed on
the basis of gadolinium content/kg of animal weight. This experi-
mental paradigm allows direct comparison of the three signals because
it should equalize the amount of gadolinium per animal, even though
it would reduce the targeting peptide in the SBK2 probe by approxi-
mately one third. The SBK2 probe provided enhanced contrast over
both ProHance and the scrambled probe, which also contained the
three gadolinium groups. The presence of the three gadolinium groups
and the higher relaxivity of the SBK2 probe contribute to its ability to
function as a better contrast agent than ProHance. The kinetics sug-
gest that the binding of SBK2 to the target has a fast off rate, likely
because it binds homophilically to PTPμ fragments in the tumor micro-
environment, which is a lower affinity interaction than that observed
in high affinity binding such as with antibodies. This is advantageous
because it promotes probe clearance from the tumor tissue and body.
The SBK2 probe is specifically and actively targeting GBM cells
and is not exploiting the enhanced permeability and retention (EPR)
effect to reach the tumor microenvironment. The EPR effect is a means
of passively targeting tumor tissue and is currently used to direct lipo-
philic therapeutic and imaging macromolecules to tumors [10,11]. The
SBK2 probe uses an active targeting strategy by homophilically binding
to the PTPμ fragment in the GBM tumor microenvironment and, at
4.7 kDa, is too small to be retained through an EPR mechanism [11].
Given that the scrambled probe, which has similar lipophilicity and
size to the SBK2 probe, does not target the tumor as efficiently further
confirms that EPR is not responsible for the binding of SBK2 probe
to the GBM cells.
The SBK2 probe offers several advantages over other MR molecular
imaging reagents used to target cell surface proteins (see [12–15]), in-
cluding a fast time course to achieve peak labeling and rapid clearance
from tumor tissue. The time course of peak labeling with the SBK2
Figure 6. Biodistribution of gadolinium in the major organs and tissues of mice at 7 days after intravenous administration of ProHance,
scrambled Tris-(Gd-DOTA)3, or SBK2-Tris-(Gd-DOTA)3 contrast agents at a dose of 0.1 mmol Gd/kg in nu/nu athymic mice bearing
LN-229 flank tumors (n = 3 mice per condition). Data shown as means ± SEM (*P < .05, **P < .001 compared to ProHance).
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probe occurs within 15 minutes (Figure 5), while the SBK2 probe
levels decline rapidly in the tumor tissue, typically at 2 hours (Figure 5)
with clearance from most tissues of the body by 7 days (Figure 6).
Peak binding for other cell surface probes occurs within 1 to 4 hours
post-injection [12–15], and in the case of integrin binding RGD lipo-
somes and nanoparticles, the rate of clearance is much slower,
beginning 24 to 48 hours after injection [12,15].
The SBK2 probe may also function better than antibodies linked to
contrast agents that are currently in development as MR molecular
imaging reagents [3,16,17]. As a 4.7-kDa peptide-based probe, SBK2-
Tris-(Gd-DOTA)3 is much smaller than an antibody and, therefore, is
expected to have superior tissue penetration. Because PTPμ is endoge-
nously processed and continuously deposited in tumor tissue to give rise
to the extracellular fragment product, no additional exogenous amplifi-
cation is required to visualize the probe. An anti-epidermal growth factor
receptor (EGFR) antibody developed to visualize GBM cells requires an
exogenous amplification step to provide sufficient contrast enhancement
in vivo [3]. This added step necessitates that the anti-EGFR antibody be
injected 5 hours before the injection of the contrast agent [3], making it
less suitable than the SBK2 probe for use in a clinical setting.
To conclude, the SBK2-Tris-(Gd-DOTA)3 probe is a rapid and
specific marker of glioma cells using MRI. This study has established
that the targeted SBK2-Tris-(Gd-DOTA)3 probe is effectively delivered
to LN-229 tumors for enhanced contrast and can be quickly cleared
from the animal. A fluorescent SBK2 probe can cross the blood-brain
barrier, even in areas of the brain where it is largely intact, to label most
dispersive cells in GBM tumors [6]. Because GBM cells tend to migrate
as chains of cells [6,18] or can exist as “cellular sheets” [19], we spec-
ulate that the SBK2-Tris-(Gd-DOTA)3 probe could effectively cross
the blood-brain barrier and label these dispersive cell chains using
MRI technology. Future studies will explore the use of this probe in
orthotopic intracranial glioma tumors and test whether the SBK2 probe
used with MRI can achieve the high resolution required to detect
chains of dispersive GBM cells.
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